{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-028146","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.519963+00:00","generated_at":"2026-05-26T16:47:27.888331+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Solid Biosciences prices $200M underwritten offering; extends cash runway into first half 2027","bullets":["Priced $200M underwritten offering expected to close Feb 19, 2025; net proceeds to fund R&D for SGT-003 and other candidates.","Company estimates cash runway into first half of 2027, but notes offering alone may not fully fund development of all candidates.","Remaining proceeds for general corporate purposes; existing cash and securities combined for operating plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-028146","json":"https://secwatch.observer/filing/0001193125-25-028146.json","markdown":"https://secwatch.observer/filing/0001193125-25-028146.md","text":"https://secwatch.observer/filing/0001193125-25-028146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525028146/0001193125-25-028146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525028146/d916580d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:47:27.888331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}